0001700449-17-000003.txt : 20170313 0001700449-17-000003.hdr.sgml : 20170313 20170313155712 ACCESSION NUMBER: 0001700449-17-000003 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20170313 DATE AS OF CHANGE: 20170313 EFFECTIVENESS DATE: 20170313 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arix Bioscience plc CENTRAL INDEX KEY: 0001700449 IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-282151 FILM NUMBER: 17685173 BUSINESS ADDRESS: STREET 1: 20 BERKELEY SQUARE CITY: LONDON STATE: X0 ZIP: W1J 6EQ BUSINESS PHONE: 44(0)20 7290 1050 MAIL ADDRESS: STREET 1: 20 BERKELEY SQUARE CITY: LONDON STATE: X0 ZIP: W1J 6EQ D/A 1 primary_doc.xml X0707 D/A LIVE 0001700449 Arix Bioscience plc 20 BERKELEY SQUARE LONDON X0 UNITED KINGDOM W1J 6EQ 44(0)20 7290 1050 UNITED KINGDOM Arix Bioscience Limited Perceptive Bioscience Investments Limited None Other Public Company in the United Kingdom true 2015 Joseph Anderson 20 BERKELEY SQUARE LONDON X0 UNITED KINGDOM W1J 6EQ Executive Officer Director Christopher Evans 20 BERKELEY SQUARE LONDON X0 UNITED KINGDOM W1J 6EQ Executive Officer Director Jonathan Peacock 20 BERKELEY SQUARE LONDON X0 UNITED KINGDOM W1J 6EQ Executive Officer Director John Mutton of Furness 20 BERKELEY SQUARE LONDON X0 UNITED KINGDOM W1J 6EQ Director James Rawlingson 20 BERKELEY SQUARE LONDON X0 UNITED KINGDOM W1J 6EQ Executive Officer Director John Banham 20 BERKELEY SQUARE LONDON X0 UNITED KINGDOM W1J 6EQ Director David U'Prichard 20 BERKELEY SQUARE LONDON X0 UNITED KINGDOM W1J 6EQ Director Franz Humer 20 BERKELEY SQUARE LONDON X0 UNITED KINGDOM W1J 6EQ Director Trevor Jones 20 BERKELEY SQUARE LONDON X0 UNITED KINGDOM W1J 6EQ Director Other Health Care Decline to Disclose 06b true 0001700449-17-000002 2017-02-22 false true false 0 Jefferies International Limited None None None 68 Upper Thames Street London X0 UNITED KINGDOM EC4V 2AF CA CALIFORNIA IL ILLINOIS false 124560000 17943967 106616033 Offering was launched as public offering in the United Kingdom and available to U.S. investors by private placement. Offering raised approx. $124,560,000 total with approx. $17,943,967 raised in the U.S. and approx. $106,616,033 in the U.K. false 4 536417 0 550000 true false Arix Bioscience plc James Rawlingson James Rawlingson Director 2017-03-13